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Protein degradations and proteins that direct early embryonic development. Although subsequent
development requires the timely degradation of these maternal products, little is known of the underlying
mechanisms. The stem-loop-binding protein (SLBP), which regulates the stability and translation of mRNAs
encoding histones and is synthesized during S-phase and degraded during G2 in somatic cells, accumulates
during oogenesis. Maternal SLBP is required for mouse embryos to develop beyond the 2-cell stage, but must
be degraded to allow the cell-cycle-regulated expression of somatic cells to be established. We report that the
quantity of maternal SLBP changes little following fertilization until 44–52 h post-hCG, corresponding to
mid-/late G2 of the 2-cell stage, when it decreases by 75%. Efﬁcient degradation requires two pathways. The
ﬁrst requires activity of cyclin-dependent kinases (cdk) and embryonic transcription, preferentially targets
nuclear SLBP, and likely corresponds to the pathway that degrades SLBP at G2 in somatic cells. The second
does not require cdk activity or transcription and becomes active at 44–52 h post-hCG independently of cell-
cycle progression to mid-/late G2, but is not solely regulated by the time elapsed since hCG injection. Thus,
the co-ordinated activity of two separately regulated pathways eliminates maternally encoded SLBP from
early mouse embryos.
© 2009 Elsevier Inc. All rights reserved.Introduction
Growing oocytes accumulate messenger RNAs (RNAs) and
proteins that direct early embryonic development (Bettegowda et
al., 2007; Cui and Kim, 2006; Stitzel and Seydoux, 2007). Following
fertilization, these maternal gene products are degraded. This
degradation, combined with the transcriptional activation of the
embryonic genome, brings development under the control of the
embryonic genome. Recent studies have begun to reveal the
mechanisms underlying the degradation of maternal products. In
Caenorhabditis elegans, phosphorylation of the OMA-1 protein during
meiotic maturation of the oocyte targets it for degradation in the
early embryo (Lu and Mains, 2007; Nishi and Lin, 2005; Shirayama et
al., 2006; Stitzel et al., 2006). Importantly, embryos that fail to
degrade OMA-1 (or anther maternally supplied protein, MEI-1) die
during early development (Bowerman and Kurz, 2006; Lin, 2003;
Stitzel and Seydoux, 2007), illustrating that correctly regulated
degradation of maternal products is essential for normal embryogen-Hospital 687 Pine Avenue W.,
rke).
iversity, Kingston, ON, Canada.
l rights reserved.esis. Apart from this case, however, this process is poorly understood.
In mammals, for example, maternal mRNA begins to be degraded
during meiotic maturation and in the mouse is largely complete by
the late 2-cell stage when embryonic transcription begins (Alizadeh
et al., 2005; Paynton et al., 1988); however, its molecular basis has
not been elucidated. Moreover, almost nothing is known of the fate of
the encoded proteins.
The stem-loop-binding protein (SLBP) plays a central role in the
metabolism and translation of most histone-encoding mRNAs (Martin
et al., 1997; Wang et al., 1996). SLBP binds to a stem-loop structure in
the 3′-untranslated region of these mRNAs and this event promotes
binding of the U7 snRNP to a site 3′ of the SLBP-binding site. The new
transcript is then cleaved between the stem-loop and U7-binding site
(Dominski et al., 1999, 2001, 2005; Jaeger et al., 2006; Kolev and Steitz,
2005). This processing reaction stabilizes the transcripts, which would
otherwise be rapidly degraded. SLBP then accompanies the histone
mRNAs to the cytoplasm, where it bridges the 3′- and 5′-ends of the
mRNA through an interaction with eIF4G and promotes their
translation (Cakmakci et al., 2008; Gorgoni et al., 2005; Ling et al.,
2002; Sanchez and Marzluff, 2002; Whitﬁeld et al., 2004); the role of
the stem-loop and SLBP in translation of histone mRNAs is analogous
to that of the poly(A) tail and poly(A)-binding proteins in translation
of polyadenylated mRNAs.
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of the cell cycle, thus co-ordinating histone synthesis with DNA
replication (Whitﬁeld et al., 2000). Following the completion of DNA
replication, SLBP-bound histone mRNAs become degraded (Mullen
and Marzluff, 2008) and the now free SLBP is transported to the
nucleus (Erkmann et al., 2005). It becomes phosphorylated on Thr-61
by the cyclin-dependent kinase (cdk) complex, CDC2A (cdk1)-cyclin A
(Koseoglu et al., 2008), which is active during G2 and is localized in the
nucleus (Pines and Hunter, 1991). This phosphorylation and subse-
quent phosphorylation of Thr-60 by casein kinase-2 trigger degrada-
tion of SLBP (Koseoglu et al., 2008; Zheng et al., 2003). Degradation
requires the activity of the skp1-cullin-F-box (SCF) ubiquitin ligase
(Yen and Elledge, 2008). Thus, in somatic cells, SLBP expression is cell
cycle-regulated, and its degradation at G2 is controlled by a ubiquitin-
mediated pathway that requires SLBP phosphorylation by CDC2A-
cyclin A and, based on the intracellular location of this kinase, likely
nuclear localization.
SLBP is also expressed in oocytes, although these are not under-
going DNA replication (Allard et al., 2002; Wang et al., 1999). It begins
to accumulate when G2-arrested oocytes enter the growth phase
(Arnold et al., 2008) and a further substantial accumulation occurs
during meiotic maturation. Following fertilization, SLBP remains
abundant throughout the ﬁrst cell cycle and following ﬁrst cleavage.
It is then degraded during the latter portion of the second embryonic
cell cycle (Allard et al., 2002). Embryos that lack maternally encoded
SLBP are unable to progress beyond the 2-cell stage, owing to a failure
to accumulate sufﬁcient histones to support chromatin assembly
(Arnold et al., 2008). Thus, maternally supplied SLBP is required for
early embryonic development; however, it must be degraded to allow
the S-phase-restricted pattern of expression that characterizes
somatic cells to be established. In the experiments reported here,
we have deﬁned that precise timing and underlying mechanisms that
regulate the degradation of this maternal gene product.
Materials and methods
Collection of eggs and embryos
All experiments were performed using CD-1 mice (Charles River
Canada) in compliance with the regulations and policies of the
Canadian Council on Animal Care. Ovulated eggs and fertilized
embryos were obtained as described (Allard et al., 2002) For
parthenogenetic activation, ovulated eggs collected at 18 h post-hCG
were exposed to 10 mM SrCl2+ for 2 h in Ca2+-free KSOM. Activated
eggs were identiﬁed by the presence of two pronuclei. For each
experiment, embryos collected from several different females were
pooled. Groups of embryos from this pool were randomly collected
and allocated to each treatment group.
Immunoblotting
Eggs or embryos at the appropriate stage of development were
transferred into a 0.5-ml microtube to which was added 10 μl of
Laemmli buffer. Tubes were heated to 95 °C for 5 min, then used
immediately or stored at −80 °C until use. All treatment groups from a
particular experiment were loaded onto the same gel and processed
identically. Proteins were separated by polyacrylamide gel electro-
phoresis in 12% polyacrylamide gels and transferred to PVDF
membrane (GE Healthcare, Montreal, QC) following standard proto-
cols (Harlow and Lane, 1999). Membranes were blocked for 1 h in Tris-
buffered saline (TBS) containing 5% non-fat milk and 0.1% Tween-20
(Sigma Chemicals, Windsor, ON), then incubated in primary antibody
diluted appropriately in TBS containing 5% bovine serum albumin
(Sigma) and 0.1% Tween-20 buffer overnight at 4 °C with gentle
agitation. The membranes were then washed in TBS, 0.1% Tween-20,
incubated in anti-rabbit-IgG or antimouse-IgG conjugated to horse-radish peroxidase (Promega, Madison, WI) diluted 1:5000 in blocking
buffer for 1 h at room temperature, and washed as above. Signals were
detected using ECL+ (GE Healthcare) and recorded on ﬁlm and using a
Phosphoimager (GE Healthcare). All data analysis was carried out
using the quantitative data obtained using the phosphoimager. For
each experiment, values were normalized to a control group on the
same blot.
Immunoﬂuorescence
Embryos were exposed brieﬂy (∼10 s) to warm acid Tyrode's
medium (Sigma) to remove the zona pellucida, washed in HEPES-
buffered KSOM medium, then ﬁxed for 15 min in freshly prepared 4%
para-formaldehyde in phosphate-buffered saline (PBS). Embryos were
blocked in PBS containing 3% BSA, 0.1% Tween-20, then incubated in
primary antibody diluted in blocking buffer overnight at 4 °C with
gentle agitation. They were then washed twice in blocking buffer,
incubated in anti-rabbit-IgG conjugated to Alexa 488 (1:200,
Molecular Probes, Eugene, OR) or to Cy3 (Jackson Immunoresearch)
for 1 h. DNA was stained using DAPI (2.5 μg/ml, Roche) or YOYO-1
(1:20000 from stock; Molecular Probes) added to the solution
containing the secondary antibody. Embryos were then washed,
mounted in Moviol and covered with glass cover slips. In the
experiments employing drug treatments, control and treated embryos
ﬁxed at the same time were mounted on the same slide. Images were
analyzed using a Zeiss CLSM 510. For each experiment, the conditions
for collecting images were established using 44-hour embryos such
that the signal remained below saturation. The optical section
containing the brightest signal was identiﬁed for each embryo and
the signal was recorded. Thus, for each experiment, all embryos were
sampled using identical parameters. Images were stored as TIFF ﬁles
and quantiﬁed using ImageJ (National Institutes of Health). For each
experiment, the mean value at 44 h was set to 1 and the mean and
standard error of the mean for each group were calculated and
normalized to this value.
Antibodies
Afﬁnity-puriﬁed anti-SLBP (Arnold et al., 2008) was diluted 1:4000
for immunoblotting and 1:200 for immunostaining. Anti-tubulin
(Cedarlane Laboratories, Burlington, ON) was used at a dilution of
1:5000. Anti-MAPK1/3 (Santa Cruz Biochemicals, Santa Cruz, CA) was
used at a dilution of 1:2000.
Drug treatments
Stock concentration, working concentration and supplier for drugs
used in this study were as follows. Aphidicolin (1 mg/ml water, 1 μg/
ml, Sigma); α-amanitin (1 mg/ml water, 10 μg/ml, Sigma); MG132,
roscovitine, 6-dimethylaminopurine (DMAP) (10 mM DMSO, 25 μM,
Sigma). The activity of roscovitine, α-amanitin, and 6-DMAP was
veriﬁed in each experimental replicate by their ability to inhibit
cleavage of an aliquot of embryos from the 2- to 4-cell stage.
Real-time reverse transcription and polymerase chain reaction (RT-PCR)
Fifty embryos were deposited into a microfuge tube and 10 pg of
EGFP mRNAwas added to the tube. RNAwas isolated using a Picopure
RNA kit (Arcturus, MDS Analytical Technologies, Toronto, ON)
following the manufacturer's instructions and resuspended in a ﬁnal
volume of 20 μl. To generate cDNA, 8.5 μl of the RNA solution was
combined with 50 ng of random hexamers (Invitrogen, Burlington,
ON), dNTPs and 50 U of Superscript II RT (Invitrogen) following the
manufacturer's recommendations in a ﬁnal volume of 20 μl. For each
sample, an identical RT reaction was assembled but omitting the
reverse transcriptase. PCR was performed using Qiagen Quantitect
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Standard curves for SLBP and EGFP were generated to calculate the
efﬁciency of ampliﬁcation for each primer pair. For analytical
reactions, 1 μl of 1:10 diluted reverse-transcription product was
used in a ﬁnal volume of 20 μl. The cycle conditions were as follows:
10 s at 94 °C, 10 s at 50 °C and 30 s at 72 °C for 50 cycles. Melting curve
analysis and agarose gel electrophoresis were performed to verify that
only the expected product was ampliﬁed. The relative expression ratio
between samples was calculated from the ampliﬁcation efﬁciencies
and the crossing points as described (Pfafﬂ, 2001).
The following primers were used, shown in 5′–3′ orientation. Slbp
(GenBank NM_009193): TGATGTGGAGACGGATGAAA, AGCAGGAG-
GATCCCAAAAAT; Egfp (GenBank U55762): GAAGTTCATCTGCAC-
CACCG, CTCAGGTAGTGGTTGTCG.
Production of embryos lacking chromosomes
Ovulated eggs were recovered 16 h post-hCG and exposed to SrCl2+
as above. At 18.5 h, those that had emitted the second polar body,
indicating that they had been activated, were selected and the
chromosomes were removed. To achieve this, the activated eggs were
incubated for 10 min in KSOM–HEPES containing the DNA vital stain,
bisbenzimide (Hoechst 33342; 5 mg/ml; Sigma), and 7.5 mg/ml
cytochalasin B (CB). Oocytes were then transferred into a 50-μl droplet
of KSOM–HEPES + CB covered with mineral oil and the chromosomes
were removed using a Nikon inverted microscope equipped with
epiﬂuorescence. The second polar body and a small portion of theFig. 1. SLBP is degraded at the late 2-cell stage. (A) Metaphase II eggs and 2-cell embryo
antibodies that recognize SLBP,α-tubulin, andMAPK1/3. Fluorescent signals were quantiﬁed
experiment, all treatment groups contained the same number (25–40) of embryos. Left side s
independent experiments for each data point, except for 2 values only for tubulin at 48 h.
pb0.05). (B) 2-cell embryos were collected at 44 h and at 52 h following incubation in th
experiments. For each protein, different subscripts indicate statistical signiﬁcance (t-test, pb0
PCR. Results are normalized to quantity of SLBP present in metaphase II eggs. Results of four i
(t-test, pb0.05). (D) Some MG132-treated embryos were treated with phosphatase before
phosphatase treatment.surrounding cytoplasm were removed and brieﬂy exposed to ultra-
violet irradiation to conﬁrm that they contained the chromosomes.
The time of chromosome removal ranged from 19 to 23 h post-hCG
injection and the nuclear stage of the activated eggs ranged from
telophase II to early pronuclear. The egg fragments were then
incubated in KSOM under standard conditions and samples were
harvested at different times as indicated in the results.
Results
To precisely deﬁne the timing of the loss of SLBP in 2-cell embryos,
unfertilized eggs were collected at 14–16 h post-hCG and 2-cell
embryos at 44, 48 and 52 h post-hCG (hereafter we omit post-hCG
except where clarity requires it) and immunoblotted to determine the
relative quantity of SLBP, tubulin and MAPK1/3 at these times.
Embryos had completed the second round of DNA replication by
40 h and begun to cleave to the 4-cell stage by 52–54 h (data not
shown), meaning that they were at mid-/late G2 during the period of
study. As compared to the amount present in unfertilized eggs, SLBP
had declined slightly by 44 h (Fig. 1A). Over the next 8 h, however, the
amount of SLBP decreased substantially, so that 52-h embryos
contained only about one-quarter of the amount present in 44-h
embryos. In contrast, the quantity of α-tubulin and MAPK1/3 did not
signiﬁcantly change during the same period. The decrease in SLBP was
completely suppressedwhen embryos were incubated in the presence
of the proteasomal inhibitor, MG132 (Fig. 1B). These results demon-
strated that most of the SLBP present in early embryos becames were collected at the indicated times post-hCG injection and immunoblotted using
using a phosphorimager and normalized tometaphase II eggs on the same blot. For each
hows a representative immunoblot. Right side shows combined results derived from 4–7
For each protein, different superscripts indicate statistical signiﬁcance (ANOVA, Tukey,
e presence or absence of MG132. Graph shows combined results from 5 independent
.05). (C) Embryoswere collected at the indicated times and analyzed using real-time RT-
ndependent experiments are shown. Different subscripts indicate statistical signiﬁcance
immunoblotting. Arrow shows the slow-migrating species that disappeared following
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occurred through a proteasome-dependent pathway.
To determine the abundance of SlbpmRNA during the periodwhen
the protein was lost, embryos were collected at 24, 44, and 52 h and
the relative amounts of SlbpmRNAweremeasured using real-time RT-
PCR. Fig. 1C shows that 90% of the Slbp mRNA present in 1-cell
embryos at 24 h had been lost by 44 h. Little further decline occurred
during the next 8 h. The relatively small amount of encoding mRNA
present in 44-h and 52-h embryos suggests that little if any SLBP was
synthesized during this period. Therefore, most or all of the SLBP that
was degraded during this time was maternally encoded and had been
synthesized earlier than 44 h.
SLBP is present in both the nucleus and cytoplasm of oocytes and
early embryos (Allard et al., 2002). In view of the observation that
about one-quarter of the SLBP was not degraded between 44 h and
52 h, we examined whether this remaining SLBP was localized in
either cellular compartment. Embryos were ﬁxed at 44 and 52 h,
stained using anti-SLBP, and the ﬂuorescent signals in the nucleus
and cytoplasm were recorded and quantiﬁed. As shown in Fig. 2,
both nuclear and cytoplasmic SLBP declined between 44 h and 52 h.
One of the blastomeres of the 52-h embryo shown in Fig. 2A had
entered metaphase, conﬁrming that by this time the embryos were
near the end of the second cell cycle. Nonetheless, most 52-h
embryos retained apparently intact nuclei, indicating that the loss of
SLBP preceded entry into metaphase. However, there was little
change in the nucleo-cytoplasmic ratio between 44 h and 52 h. This
result indicated that both nuclear and cytoplasmic SLBP were
degraded during this period.
As discussed in the Introduction, degradation of SLBP in somatic
cells requires its phosphorylation during G2 by the cdk complex,
CDC2A-cyclin A (Koseoglu et al., 2008; Zheng et al., 2003). MG132-
treated 2-cell embryos exhibited a slow-migrating species of SLBP that
was eliminated by phosphatase treatment prior to electrophoresisFig. 2. SLBP is lost from both nuclear and cytoplasmic compartments. (A) Two-cell embryo
binding dye and examined using confocal microscopy. The ﬂuorescent signal was quantiﬁed
the 52-h embryo has entered metaphase. Right side shows the density of nuclear and cytopl
(right-most bars). 38 cells analyzed at 44 h, 50 at 52 h. Different subscripts within each pai
embryos were treated with roscovitine from 44–52 h. 58 cells analyzed at 44 h, 72 at 52 h,
indicate statistical signiﬁcance (ANOVA, Tukey, pb0.05). Scale bar=20 μm.(Fig. 1), suggesting that SLBP in embryos also became phosphorylated
prior to its degradation. To test whether cdk activity was required for
SLBP degradation in embryos, these were transferred to medium
containing the cdk inhibitor, roscovitine, at 44 h and samples were
collected at 48 h and 52 h. Roscovitine selectively inhibits CDC2A,
CDK2 and CDK5 (Meijer et al., 1997), and its effectiveness was
conﬁrmed in each experiment by its ability to prevent the second
cleavage division (data not shown). At both 48 h and 52 h, the
roscovitine-treated embryos contained signiﬁcantly more SLBP than
control embryos at the same time-point (Fig. 3, indicated by asterisks).
SLBP nonetheless became degraded in the roscovitine-treated
embryos (Fig. 3, indicated by different letters above the columns),
albeit at a slower rate than in controls. Similar results were observed
when the drug was added at 48 h (Fig. 3) and at two-fold higher or
lower doses (not shown). These results indicated that cdk activity was
required to fully activate the mechanism of SLBP degradation in 2-cell
embryos.
As the major activation of embryonic gene transcription occurs
during the latter half of the 2-cell stage (Bultman et al., 2006; Latham,
1999), we then tested whether SLBP degradation required transcrip-
tion. Embryos at the late 1-cell stage (32 h post-hCG) were transferred
toα-amanitin, an inhibitor of RNA polymerase II, and collected at 52 h.
Drug-treated embryos underwent the ﬁrst cleavage division, but did
not undergo second cleavage (data not shown), conﬁrming the
effectiveness of the drug. As observed in the roscovitine-treated
embryos, exposure to α-amanitin partially suppressed the degrada-
tion of SLBP from 44–52 h (Fig. 4A, left side). Taken together, these
results indicated that efﬁcient degradation of SLBP in 2-cell embryos
required cdk activity and embryonic transcription.
It was evident, however, that a signiﬁcant fraction of SLBP was
degraded even in the presence of roscovitine or α-amanitin. Although
each drug completely prevented the second cleavage division, the
incomplete suppression of degradation could indicate that each drugs were collected at the indicated times post-hCG, stained using anti-SLBP and a DNA-
using NIH Image J. Left side shows a representative image. The left-hand blastomere in
asmic staining, normalized to nuclear density at 44 h, and the nuclear:cytoplasmic ratio
r of bars indicate statistical signiﬁcance (t-test, pb0.05). (B) As in (A) except that some
and 76 following roscovitine treatment. Different subscripts within each group of bars
Fig. 4. Degradation of SLBP is partially suppressed by inhibitors of transcription and
protein phosphorylation. (A) Two-cell embryos were incubated in the presence of
vehicle or of α-amanitin added at 32 h post-hCG (left blot and group of bars) or of α-
amanitin added at 32 h, roscovitine added at 44 h, or both (right blot and group of bars).
They were collected at the indicated times and immunoblotted using antibodies that
recognize SLBP and α-tubulin. Upper panel shows a representative immunoblot. Lower
panel shows combined results of six (left) or three (right) independent experiments. In
each experiment, values were normalized to the quantity present at 44 h. All groups
contained signiﬁcantly less SLBP than the 44-h embryos. Different superscripted letters
indicate signiﬁcant differences within a group (ANOVA, Tukey, pb0.05). No signiﬁcant
changes in the quantity of tubulinwere detected. (B) As in (A) except that embryos were
exposed to 6-DMAP from 44–52 h. Representative immunoblot (left) and combined
results (right) of three independent experiments. For SLBP, but not tubulin, the 6-
DMAP-treated group differed signiﬁcantly from the 44-h and 52-h groups (t-test,
pb0.05).
Fig. 3. Degradation of SLBP is partially suppressed by an inhibitor of cdk activity. Two-
cell embryos were incubated in the presence of DMSO or roscovitine added at 44 h or
48 h post-hCG, collected at the indicated times, and immunoblotted using antibodies
that recognize SLBP and α-tubulin. Representative immunoblot (upper) and combined
results (lower) of ﬁve independent experiments. In each experiment, values were
normalized to the quantity present at 44 h. All groups contained signiﬁcantly less SLBP
than the 44-h embryos, except for the roscovitine-treated group at 48 h (t-test, pb0.05).
Different superscripted letters indicate signiﬁcant differences within a group, and an
asterisk indicates a signiﬁcant difference as compared to DMSO-treated embryos at the
same time-point (ANOVA with Tukey for group with 3 time-points, t-test for groups
with 2 time-points, pb0.05). No signiﬁcant changes in the quantity of tubulin were
detected.
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possibility in two ways. First, we reasoned that, if this were the case,
incubating embryos in the presence of both drugs would suppress
degradation more efﬁciently. To test this, embryos were incubated in
the presence of roscovitine or α-amanitin alone or together and
collected at 52 h. As shown in Fig. 4A (right side), both drugs
suppressed SLBP degradation, and they did so to the same extent.
However, no additional suppression was observed in the presence of
both drugs. Second, we tested the effect of a general inhibitor of
protein phosphorylation, 6-DMAP. Like roscovitine, 6-DMAP partially
suppressed the degradation of SLBP between 44 h and 52 h (Fig. 4B).
Moreover, it exerted a quantitatively similar effect – about 50–60% of
the SLBP present at 44 h remained at 52 h in the presence of either
drug. Thus, two drugs that inhibit cdk-dependent protein phosphor-
ylation by different mechanisms each partially suppressed SLBP
degradation. These results argued against the possibility that the
partial suppression of SLBP degradation by these drugs was due to
incomplete inhibition of their targets.
Cyclin A is localized in the nucleus in somatic cells (Pines and
Hunter,1991), andwe observed that it is also nuclear in 2-cell embryos
as judged by immunoﬂuorescence (data not shown). Yet the
cytoplasmic SLBP in these cells was nonetheless degraded between
44 h and 52 h (Fig. 2). This suggested that degradation of cytoplasmic
SLBP might not require CDC2A-cyclin A activity. To test this idea,
embryos were treated with roscovitine from 44–52 h, then processed
for immunoﬂuorescence. As shown in Fig. 2B, the intensity of
cytoplasmic ﬂuorescence decreased between 44 h and 52 h, although
to a slightly lesser extent than in controls. In contrast, nuclear
ﬂuorescence remained unchanged during this period in the presence
of the drug. Thus, roscovitine preferentially suppressed the loss ofnuclear SLBP. This implies that cytoplasmic SLBP could be degraded by
a cdk-independent pathway.
These results described above indicated that SLBP became
degraded between 44 h and 52 h post-hCG, corresponding to mid-/
late G2 of the 2-cell stage, and that degradation could occur through
both roscovitine-sensitive and -insensitive pathways. Although
degradation occurred when the embryos were at G2, its timing
could in principle be regulated by the time elapsed since hCG injection
rather than by cell-cycle progression. Therefore, we sought a means to
separate these two parameters. To this end, we activated eggs
parthenogenetically at 18 h post-hCG. Since fertilization in vivo occurs
at ∼12 h post-hCG, cell-cycle progression of the parthenogenetic
embryos was retarded by ∼6 h as compared to fertilized embryos. We
then determined whether SLBP became degraded between 44 h and
52 h in the developmentally delayed parthenogenetic embryos. Fig. 5A
shows that SLBP became degraded during this period. However, it was
degraded to a lesser extent (∼50%) than in fertilized embryos (∼75%).
We then tested whether this degradation required cdk activity. In
contrast to the results observed using fertilized embryos, roscovitine
did not detectably suppress the partial degradation of SLBP in
parthenogenetic embryos (Fig. 5B). These results indicated that a
pathway of SLBP degradation became active between 44 and 52 h
post-hCG independently of cell-cycle progression to mid-/late G2, and
that this pathway was not suppressed by roscovitine.
Fig. 5. A pathway that becomes active independently of progression to mid-/late G2 triggers degradation of SLBP. (A) Unfertilized eggs were parthenogenetically activated at 18 h
post-hCG, then collected at the indicated times and immunoblotted using antibodies that recognize SLBP and α-tubulin. Representative immunoblot, including fertilized embryos
collected during the same experiment (left) and combined results of ﬁve independent experiments (right). In the immunoblot, the time of collection is indicated both in h post-hCG
and in h post-activation, assuming that fertilization occurred 12 h post-hCG. (B) As in (A) except that a group of embryos was treated with roscovitine from 44–52 h. Five independent
experiments. (C) Unfertilized eggs were parthenogenetically activated at 16.5–17 h post-hCG and the chromosomes were removed at between 19 and 23 h from those that had
emitted the second polar body. Samples were collected at the indicated times post-hCG. Three independent experiments. Different superscripts indicate statistical signiﬁcance
(ANOVA with Tukey or t-test, pb0.05).
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degradation was regulated solely by the time elapsed since the hCG
injection. Eggs were parthenogenetically activated at 16–17 h post-
hCG, allowed to complete the second meiotic division so that
successfully activated eggs could be selected, and the chromosomes
were removed. This produced cytoplasts that would be unable to
undergo chromosome-dependent cell cycle and developmental
events. Cytoplasts were collected immediately after chromosome
removal (19–23 h) and at 38 h, 44 h and 52 h post-hCG. As shown in
Fig. 5C, there was no signiﬁcant change in the quantity of SLBP during
this time. This suggests that, although a pathway of SLBP degradation
is linked to the time elapsed since hCG injection, its activity requires
progression through embryonic development.
Discussion
We have examined the timing and pathways responsible for the
degradation of maternally encoded SLBP in mouse embryos. The
amount of SLBP changes little after fertilization until the period from
44–52 h post-hCG, corresponding to mid-/late G2 of the 2-cell stage,
when it declines by about 75%. Both nuclear and cytoplasmic SLBP are
degraded and degradation requires proteasomal activity. Degradation
is partially suppressed or delayed by inhibition of cdk activity, and theloss of nuclear SLBP is preferentially suppressed. Degradation is also
partially suppressed when embryonic transcription is inhibited;
however, no additional suppression occurs when both cdk activity
and transcription are inhibited. SLBP is partially degraded between 44
and 52 h post-hCG in parthenogenetic embryos that have not yet
reached mid-/late G2, and this degradation is not suppressed by cdk
inhibition. Degradation does not occur, however, in embryos from
which the chromosomes have been removed. These results identify
the pathways that mediate the degradation of maternally encoded
SLBP, a prerequisite for the somatic pattern of SLBP expression to be
established.
The characteristics of SLBP degradation in 2-cell embryos resemble
those observed in somatic cells in several respects. In both cases,
degradation occurs during G2 by a proteasome-dependent pathway
(Whitﬁeld et al., 2000; Zheng et al., 2003). As well, efﬁcient
degradation requires activity of a cdk. In somatic cells has been
identiﬁed as CDC2A-cyclin A (Koseoglu et al., 2008; Zheng et al., 2003).
While we do not yet know whether CDC2A-cyclin A controls SLBP
degradation in embryos, expression of a dominant-negative form of
CDK2, which is the other principal cdk that is active during G2, in 2-
cell embryos did not inhibit SLBP degradation (W.Z. and H.J.C.,
unpublished). Certain differences between the two systems also may
be identiﬁed. Degradation of SLBP in embryos is relatively slow. Its
146 W. Zhang et al. / Developmental Biology 328 (2009) 140–147quantity fell by about 75% over a period of 8 h in the 2-cell embryos,
whereas its half-life in proliferating cells in culture is ∼2 h during S-
phase and estimated to be up to 10-fold less during G2 (Whitﬁeld et
al., 2000). As well, our results suggest that degradation occurs during
mid-/late G2 in embryos, whereas it occurs in early G2 in somatic cells
(Whitﬁeld et al., 2000). Notwithstanding these differences, our results
suggest that the mechanism that degrades SLBP during G2 in somatic
cells becomes active during G2 in 2-cell embryos, leading to extensive
degradation of maternally encoded SLBP.
SLBP does not detectably decline in 1-cell embryos, however, and it
accumulates in growing oocytes, which are at G2 (Arnold et al., 2008).
Although we cannot exclude that some SLBP is degraded during G2 of
1-cell embryos, which is much shorter than G2 of 2-cell embryos, this
suggests that the mechanism of SLBP degradation in 2-cell embryos is
not active in oocytes or 1-cell embryos. This cannot be attributed to
the absence of CDC2A or cyclin A, as these are present in growing
oocytes and 1-cell embryos (Choi et al., 1991; Fuchimoto et al., 2001;
Persson et al., 2005). Recent work has revealed that the degradation of
SLBP during G2 in somatic cells requires the SCF ubiquitin ligase (Yen
and Elledge, 2008). However, the F-box protein that recognizes SLBP
has not yet been identiﬁed. In view of the observation that embryonic
transcription is required for efﬁcient SLBP degradation, it may be
speculated that this unidentiﬁed F-box protein is not present in
oocytes and that it is synthesized upon full activation of the
embryonic genome at the mid-2-cell stage, thus enabling phosphory-
lated SLBP to be efﬁciently degraded.
Although cdk activity is required for efﬁcient degradation of SLBP,
we consistently observed that a portion of SLBP was degraded in the
presence of its inhibitor, roscovitine. While we cannot exclude that
this is due to incomplete inhibition of cdk activity by the drug, several
observations argue against this interpretation. First, treatment with
roscovitine completely inhibited the second cleavage division, which
requires cdk activity. Second, a similar partial suppression of SLBP
degradation was observed when embryos were treated with 6-DMAP
or with α-amanitin. Third, no additional suppression of degradation
occurred when embryos were treated with both roscovitine and α-
amanitin, as might have been expected if each were partially effective.
Taken together, these considerations raise the possibility that SLBP in
embryos can also be degraded by a cdk-independent pathway.
Interestingly, it was recently reported that SLBP in somatic cells is
degraded during G1 by a mechanism that requires neither SCF activity
nor SLBP phosphorylation (Yen and Elledge, 2008), consistent with the
notion of a cdk-independent pathway.
The existence of a cdk-independent pathway of SLBP degradation
may account for the degradation of the cytoplasmic SLBP in 2-cell
embryos. In somatic cells, SLBP is transported from the nucleus to
cytoplasm when bound to histone mRNA and returns to the nucleus
when dissociated from the mRNA (Erkmann et al., 2005). At G2,
almost all SLBP has returned to the nucleus where it is accessible to
CDC2A-cyclin A. In embryos, however, a signiﬁcant fraction of SLBP
remains in the cytoplasm at G2. As cyclin A is nuclear in 2-cell
embryos, it seems that this SLBP would not be accessible to CDC2A-
cyclin A. Thus, it may be questioned how it becomes degraded. It may
be speculated that the cytoplasmic SLBP in 2-cell embryos is degraded
by a cdk-independent pathway, whereas the nuclear SLBP is degraded
by the cdk-dependent pathway. Consistent with this, roscovitine
suppressed the loss of nuclear, but not cytoplasmic, SLBP in treated
embryos. A limitation of this interpretation is that we do not know to
what extent SLBP can move between the nucleus and cytoplasm in
embryos. Although there appears to be little nuclear-cytoplasmic
shuttling of free SLBP in somatic cells (Erkmann et al., 2005), we do not
know whether the same rules govern its behavior in embryonic cells.
Nonetheless, this model offers a potential rationale for the existence of
cdk-dependent and -independent pathways of SLBP degradation and
for understanding how SLBP that is not co-localized with cyclin A
becomes degraded.The notion that a cdk-independent pathway of SLBP degradation
may exist is further supported by the results observed using
parthenogenetic embryos. As these embryos were activated at 18 h
post-hCG, they were developmentally retarded by ∼6 h as compared
to fertilized embryos, which were activated ∼12 h post-hCG. There-
fore, it may be inferred that between 44 and 52 h post-hCG the
parthenotes were not progressing through the period of G2 when
SLBP degradation normally occurs. Nonetheless, SLBP became par-
tially degraded during this time, although to a lesser extent than in
fertilized embryos. This implies that a pathway of degradation that is
not strictly cell cycle-regulated became active in these embryos.
Moreover, this partial degradation was not inhibited by roscovitine.
Thus, it may be that a cdk-independent pathway of SLBP degradation
becomes active at 44–52 h post-hCG independently of cell cycle
progression to mid-/late G2.
As injection of hCG triggers meiotic maturation of pre-ovulatory
oocytes, it may be speculated that activation of the cdk-independent
pathway of SLBP degradation is linked to the time elapsed since the
initiation of maturation. Events that seem to be regulated by a clock
rather than cell-cycle or developmental progression have previously
been identiﬁed in embryos of various species (Johnson and Day, 2000).
For example, timed cortical rearrangements and cyclic changes in the
activity of a potassium channel occur in cytoplasts generated by
enucleation of 1-cell mouse embryos (Day et al., 1998; Waksmundzka
et al., 1984). SLBP degradation, however, does not occur between 44
and 52 h post-hCG in cytoplasts that lack the chromosomes. This
suggests that activation of the cdk-independent pathway of SLBP
degradation, although potentially regulated by a clock that is set
during maturation, requires progression through certain cell-cycle or
developmental stages.
In summary, our results suggest that maternally encoded SLBP is
degraded in 2-cell embryos by two pathways: a cdk- and transcrip-
tion-dependent pathway that becomes active during G2, targets
nuclear SLBP, and corresponds to the pathway that degrades SLBP at
G2 in somatic cells; and a cdk-independent pathway that becomes
active at 44–52 h post-hCG independently of cell-cycle progression to
mid-/late G2 and targets cytoplasmic SLBP. The implication of two
pathways in the degradation of maternally encoded SLBP in themouse
bears a striking similarity to observations made using D. melanogaster,
where maternal mRNAs are degraded in early embryos by two
pathways, of which one is maternally encoded and the other requires
embryonic transcription (Tadros and Lipshitz, 2005). Rapid degrada-
tion requires the activity of both pathways, but slow degradation
nonetheless occurs when only one pathway is active. It may be a
common feature of early embryonic development that maternally and
embryonically encoded pathways work co-ordinately to eliminate
maternal mRNAs and proteins, thus enabling the oocyte-to-embryo
transition to be efﬁciently completed.
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